Opening book details…
About this Medicine article
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability by ten Cate, B; Bremer, E; de Bruyn, M; Bijma, T; Samplonius, D; Schwemmlein, M; Huls, G; Fey, G; Helfrich, W is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- ten Cate, B; Bremer, E; de Bruyn, M; Bijma, T; Samplonius, D; Schwemmlein, M; Huls, G; Fey, G; Helfrich, W
- Publisher
- Nature Publishing Group; Springer Science and Business Media LLC (ISSN 0887-6924)
- Published
- 2009
- Language
- EN
- Field
- Medicine (Health Sciences)